Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic…
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments Compass Pathways plc a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for…
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026 SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for early molecular residual disease (MRD) detection, announced that the…
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, announced new preclinical data from its NEU-002…
OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform OncoNano Medicine, Inc. a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, announced it will present new preclinical data at the…
Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors Volastra Therapeutics, a clinical-stage oncology company pioneering therapies targeting chromosomal instability (CIN), announced multiple scientific disclosures coinciding with the American…
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated,…
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of Roche, announced it is set to expand its monitoring portfolio with…
Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical impact of mNGS using Delve Detect to identify pathogens and…
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC) Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients…
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225 NorthStar Medical Radioisotopes, LLC a leading radiopharmaceutical company, today announced that it received notice of the U.S. Food & Drug Administration’s (FDA) acceptance of its Type II Drug Master…
Litmys and Konovo Form Partnership to Revolutionize Drug Development Intelligence for Life Sciences Companies Litmys, a life sciences commercial strategy consulting firm, specializing in the development of commercial readiness analytics, and Konovo, a technology-first healthcare intelligence company that accelerates access to…